AIM Vaccine Co., Ltd. (HKG: 6660)
Hong Kong
· Delayed Price · Currency is HKD 5.85
-0.15 (-2.50%)
Jan 3, 2025, 4:08 PM HKT
AIM Vaccine Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | 1,184 | 1,187 | 1,264 | 1,570 | 1,638 | 951.65 |
| Revenue Growth (YoY) | -2.37% | -6.06% | -19.49% | -4.14% | 72.12% | - |
| Cost of Revenue | 1,840 | 1,799 | 236.41 | 275.43 | 267.66 | 206.6 |
| Gross Profit | -655.57 | -611.21 | 1,028 | 1,295 | 1,370 | 745.05 |
| Selling, General & Admin | 764.13 | 748.29 | 943.92 | 1,628 | 731.95 | 487.19 |
| Research & Development | 407.98 | 636.4 | 500.31 | 307.35 | 157.76 | 98.89 |
| Other Operating Expenses | - | - | - | - | 16.23 | 12.21 |
| Operating Expenses | 1,176 | 1,389 | 1,471 | 1,943 | 906.76 | 596.18 |
| Operating Income | -1,832 | -2,000 | -443.79 | -648.73 | 463.56 | 148.87 |
| Interest Expense | -54.67 | -43.83 | -25.69 | -10.7 | -15.74 | -10.78 |
| Interest & Investment Income | 9.63 | 10.71 | 10.69 | 10.78 | 10.74 | 3.67 |
| Currency Exchange Gain (Loss) | 0.66 | 0.66 | - | 2.03 | 6.12 | -1.93 |
| Other Non Operating Income (Expenses) | 21.97 | 27.52 | 21.55 | 38.25 | 21.91 | 21.94 |
| EBT Excluding Unusual Items | -1,854 | -2,005 | -437.24 | -608.38 | 486.58 | 161.77 |
| Impairment of Goodwill | -211.44 | -211.44 | - | - | - | - |
| Gain (Loss) on Sale of Investments | - | - | 3.07 | 1.67 | 1.31 | - |
| Gain (Loss) on Sale of Assets | 6.92 | 6.92 | - | - | -2.01 | -5.01 |
| Asset Writedown | -61.09 | -61.09 | - | - | - | - |
| Pretax Income | -2,120 | -2,271 | -434.17 | -606.7 | 485.89 | 156.76 |
| Income Tax Expense | -282 | -320.4 | -203.54 | 69.17 | 85.47 | 36.95 |
| Earnings From Continuing Operations | -1,838 | -1,950 | -230.63 | -675.87 | 400.41 | 119.81 |
| Minority Interest in Earnings | 648.18 | 649.24 | -88.97 | -16.9 | -21.13 | -2.41 |
| Net Income | -1,190 | -1,301 | -319.6 | -692.77 | 379.29 | 117.41 |
| Net Income to Common | -1,190 | -1,301 | -319.6 | -692.77 | 379.29 | 117.41 |
| Net Income Growth | - | - | - | - | 223.06% | - |
| Shares Outstanding (Basic) | 1,211 | 1,211 | 1,203 | 1,163 | 963 | 834 |
| Shares Outstanding (Diluted) | 1,211 | 1,211 | 1,203 | 1,163 | 963 | 834 |
| Shares Change (YoY) | 0.25% | 0.71% | 3.44% | 20.78% | 15.37% | - |
| EPS (Basic) | -0.98 | -1.07 | -0.27 | -0.60 | 0.39 | 0.14 |
| EPS (Diluted) | -0.98 | -1.07 | -0.27 | -0.60 | 0.39 | 0.14 |
| EPS Growth | - | - | - | - | 178.57% | - |
| Free Cash Flow | -142.23 | -324.42 | -889.33 | -1,032 | -416.35 | 12.23 |
| Free Cash Flow Per Share | -0.12 | -0.27 | -0.74 | -0.89 | -0.43 | 0.01 |
| Gross Margin | -55.36% | -51.47% | 81.30% | 82.46% | 83.66% | 78.29% |
| Operating Margin | -154.71% | -168.43% | -35.11% | -41.32% | 28.30% | 15.64% |
| Profit Margin | -100.48% | -109.56% | -25.28% | -44.12% | 23.16% | 12.34% |
| Free Cash Flow Margin | -12.01% | -27.32% | -70.35% | -65.73% | -25.42% | 1.29% |
| EBITDA | -1,693 | -1,859 | -307.38 | -529.57 | 569.96 | 246.14 |
| EBITDA Margin | -142.93% | -156.53% | -24.32% | -33.73% | 34.80% | 25.86% |
| D&A For EBITDA | 139.46 | 141.38 | 136.41 | 119.16 | 106.4 | 97.27 |
| EBIT | -1,832 | -2,000 | -443.79 | -648.73 | 463.56 | 148.87 |
| EBIT Margin | -154.71% | -168.43% | -35.11% | -41.32% | 28.30% | 15.64% |
| Effective Tax Rate | - | - | - | - | 17.59% | 23.57% |
Source: S&P Capital IQ. Standard template. Financial Sources.